

15 May 2019

Dietary Reference Values for sodium and chloride

Web meeting with stakeholders

Trusted science for safe food

- **EFSA working group on DRVs for minerals**
 - Androniki Naska, chair
 - Peter Aggett, member
- **EFSA Nutrition Unit**
 - Valeriu Curtui, Head of Unit (**moderator**)
 - Agnès de Sesmaisons Lecarré, staff
 - Silvia Valtueña Martinez, staff
 - Laura Ciccolallo, staff


10:00 – 10:05	Welcome and introductory remarks
10:05 – 10:35	Part 1 <ul style="list-style-type: none">• Scope and methodological framework• Identification of the criteria on which to base DRVs
10:35 – 10:50	Questions and Answers
10:50 – 11:20	Part 2 <ul style="list-style-type: none">• Data on which to base DRVs• Conclusions for each population group
11:20 – 12:00	Questions and Answers
12:00 – 12:15	Part 3 <ul style="list-style-type: none">• DRVs for chloride
12:15 – 12:30	Questions and Answers

- Please note that you will be **muted during the whole meeting** to avoid background noises
- **How to ask questions**
 - During the talks: in writing through the chat
 - During the Q&A sessions: send a message through the chat so that moderator gives you the floor (unmute)
- The meeting is **recorded** and will be **published** on the EFSA website
- Please note that you need to **submit your comments by 22 May** through the EFSA website for them to be considered

Part 1

- Scope and methodological framework
- Identification of the criteria on which to base DRVs

- Request from the European Commission
- EFSA is asked to advise on population reference intakes of micronutrients in the diet
- To review and complete the SCF recommendations from 1993, in the light of new evidence



2016

Task initiated

2017

Protocol for a systematic review

Public consultation

Protocol published

Technical Report published

2018

Protocol implementation

Completion of the draft Opinion

2019

Endorsement by the NDA Panel

Public consultation

Finalisation

July 2019

Adoption by the NDA Panel

Opinion published

Technical Report published

■ EFSA Working Group on DRVs for minerals

- Peter Aggett
- Susan Fairweather-Tait
- Ambroise Martin
- Androniki Naska
- Hildegard Przyrembel
- Alfonso Siani
- Marco Vinceti

■ EFSA staff

- Laura Ciccolallo
- Agnès de Sesmaisons Lecarré
- Silvia Valtueña Martinez

■ EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)

- | | |
|-----------------------------|---------------------|
| ■ Dominique Turck | ■ Harry J McArdle |
| ■ Jacqueline Castenmiller | ■ Androniki Naska |
| ■ Stefaan de Henauw | ■ Carmen Pelaez |
| ■ Karen-Ildico Hirsch-Ernst | ■ Kristina Pentieva |
| ■ John Kearney | ■ Alfonso Siani |
| ■ Helle Katrine Knutsen | ■ Frank Thies |
| ■ Alexandre Maciuk | ■ Sophia Tsabouri |
| ■ Inge Mangelsdorf | ■ Marco Vinceti |

1. Collection of relevant background information
2. Identification of the criteria on which to base DRVs
 - Including assessment of dose–response relationships
3. Integration of the available evidence and derivation of DRVs

- Sodium: functions, physiology and metabolism
- Interaction with other nutrients
- Biomarkers
- Effects of genotypes
- Dietary sources
- Dietary intake

- On average, **93%** of daily Na intake recovered in 24hr urine
- Reliability affected by **variations** over daily and weekly periods
- **24-hour urine collections**
 - Incomplete 24-hour urine collections can introduce errors in intake estimates
 - Na levels in 24-hour urine collections are variable
 - **Single 24-hour urine collection**
 - reliable estimate of average groups' intake
 - not a reliable measure of an individual's usual intake (random misclassification)
 - **Multiple 24-hour urine collections per individual** are preferred
- Casual/timed **spot urine** collections
 - Reliability affected by circadian variations
 - Estimates from predictive equations based on spot urine samples can be biased (ends of the distribution)

1. Biomarkers as indicators of Na requirement
2. Balance studies
3. Sodium intake and health consequences

■ Findings

- Homeostatic mechanisms maintain systemic distribution, acquisition and excretion of Na, including plasma Na concentration/activity, as a means of maintaining water homeostasis
- Hyponatraemia and hypernatraemia related to disorders affecting water and electrolyte balance; seldom due to inappropriate Na intake
- Plasma Na concentration does not accurately reflect Na body content

■ Conclusion

- **No appropriate biomarkers** of Na status that can be used for deriving DRVs for sodium

- Evidence
 - Several studies excluded because of methodological limitations
 - 3 studies in adults and 1 study in adolescents were thoroughly reviewed
- Findings
 - Balance maintained over a **wide range** of Na intake
 - Mean Na intake assessed in eligible balance studies ranged between 1.5 g and 4.9 g/day in adults and between 1.31 and 3.95 g/day in adolescents.
 - Rhythmical variations in the Na body pool **independent of Na intake**
 - Response of **sympathetic nervous system** and the **renin–angiotensin–aldosterone system** to conserve Na evident at excretion below 100mmol/24 hours
- Conclusion
 - Balance studies cannot be used to determine Na requirements
 - Can be used to inform about the levels of Na intake **adequate to maintain a null balance**.
 - Metabolic studies inform about **systemic mechanisms** to maintain a Na balance.

- Outcomes
 - Blood pressure and cardiovascular diseases
 - Bone health
- Selection criteria
 - Biological relevance for the general healthy population
 - Biological plausibility of their relationship with Na intake
 - Type of evidence (i.e. RCTs and/or prospective observational studies)
- Systematic reviews of the literature
 - Protocols published in PROSPERO and Zenodo

- Eligibility criteria


- Design: RCTs (parallel or crossover) and prospective studies
- Duration : ≥ 4 weeks for BP; ≥ 6 months for CVD outcomes; ≥ 1 year for BMD or risk of osteoporotic fractures in adults
- Population: adults (≥ 18 years) and children (6 months to < 18 years) from the general population.
- Na measurement: urinary Na excretion calculated from single or multiple 24-h urine collection(s).

- Risk of bias appraisal

- OHAT-NTP tool
- 3-tier classification: low, moderate or high risk of bias

Prisma chart

Blood
pressure and
cardiovascular
diseases



- Evidence
 - 32 eligible RCTs
 - Random effect meta-analyses on the effect of Na reduction
 - Subgroup analyses to explore contextual and methodological sources of heterogeneity
 - Mixed-effects meta-regression models (dose-response)
 - Moderating effects of age and blood pressure status explored in stratified analyses

■ Findings

- Significant effects of Na reduction on SBP **by -3.9 mmHg** (95%CI: -5.1 , -2.8 mmHg)
- Significant effects of Na reduction on DBP **by -2.0 mmHg** (95%CI: -2.8 , -1.2 mmHg)
- **Linear dose-response** over the range of mean UNa observed ($49 - 209$ mmol/24 h ($1.3 - 4.8$ g/day))
- Mean **SBP increased by 5.3 mmHg** (95% CI: 3.6 , 6.9 mmHg) for each 100 mmol (2.3 g)/24-h increase in mean UNa
- Mean **DBP increased by 2.6 mmHg** (95% 1674 CI: 1.6 , 3.7 mmHg) for each 100 mmol (2.3 g)/24-h increase in mean UNa
- Stronger association among hypertensive vs normotensive individuals and among subjects aged ≥ 50 years vs subjects < 50 years

- Evidence
 - 1 prospective cohort study (moderate RoB) on the long-term relationship between UNa and **blood pressure levels**
 - 2 RCTs (low RoB) and 2 prospective observational studies (low and moderate RoB) on the relationship between UNa and **risk of hypertension**
- Findings
 - **Support the positive relationship** between UNa and blood pressure levels derived from RCTs

- Evidence

- 2 eligible RCTs (low and moderate RoB)
- 1 prospective cohort study (PCS) (two publications) (low RoB)

- Findings

- **No evidence** from RCTs for an effect of Na reduction on blood pressure in school-age children.
- **No significant association** from PCS between UNa and blood pressure in pre-pubertal and pubertal children
- **Weak evidence** from PCS for a positive association between UNa during adolescence and SBP in adulthood


■ Evidence

- No RCT eligible
- **Small number** of PCS
 - 3 cohorts on the risk of stroke or on the risk of coronary heart disease
PREVEND (low RoB); EPOGH/FLEMENGHO and the Finnish cohort (moderate RoB)
 - 3 cohorts on the risk of cardiovascular disease
TOPHI/II (low RoB); EPOGH/FLEMENGHO and InCHIANTI (moderate RoB)
- **No quantitative analysis**

■ Findings

- Limited conclusions
- Risk of **coronary heart disease**: some evidence for a **positive** association
- Risk of **stroke**: some evidence for a **negative** association
 - Small number of studies and mechanisms unclear
- Risk of **cardiovascular disease**: some evidence for a **positive** association

Bone Health



- Evidence
 - 2 eligible papers
- Findings
 - **Limited and inconsistent** evidence for an association between Na intake and bone mineral density
 - Data **cannot be used** to set DRVs for Na

Questions & Answers


Part 2

- Data on which to base DRVs
- Conclusions for each population group

- An average requirement (AR) and a population reference intake (PRI) can NOT be established for Na, because the distribution of the requirement cannot be determined
- Data relevant to the setting of DRVs for sodium
 - Balance studies: levels of Na intake adequate to maintain a null balance
 - Relationship between Na and blood pressure or CVD risk: levels of Na associated with a reduced risk of chronic diseases
- Expert judgement, taking account of the associated uncertainties
- Use of a formal Expert Knowledge Elicitation (EKE) process

- Formal **Expert Knowledge Elicitation** (EKE) ([EFSA Guidance, 2014](#))
 - Evidence-based judgements about **a quantity of interest**
 - Judgements expressed about the range of possible values for the quantity of interest and their relative likelihood
 - Limits **bias**;
 - Structured process improves **rigour of reasoning**;
 - Clear and **unambiguous expression of uncertainty**;
 - Rationale **documented**.
- 'Sheffield' protocol
 - Method designed to elicit the knowledge of a **group of experts** in a **face-to-face** elicitation meeting
 - Result in an uncertainty probability distribution that represents the experts **aggregated judgements** achieved via **discussion**.
 - Presence of an **elicitor** essential.

1. Collective review of the 'evidence dossier'
2. A **separate distribution** is elicited from each expert in parallel;
3. The individual judgements are shared and **discussed**;
4. A **consensus distribution** (dashed curve in graph) is elicited from the experts as a group.




- **Data on Na and blood pressure or CVD risks** could inform about the levels of sodium intake associated to a reduced risk of chronic diseases

Question 1 What is the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the majority ($\geq 97.5\%$) of the general population of adults?


- **Balance studies** could inform about the levels of sodium intake which are adequate to maintain a null sodium balance

Question 2 What is the lowest level of sodium intake which is adequate (i.e. amount which allows to maintain sodium balance) for the majority ($\geq 97.5\%$) of the general population of adults?

- What is the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the majority ($\geq 97.5\%$) of the general population of adults?




- What is the lowest level of sodium intake which is adequate (i.e. amount which allows to maintain sodium balance) for the majority ($\geq 97.5\%$) of the general population of adults?



Conclusion – DRVs for adults

- A sodium intake of **2.0 g/day** represents a level of sodium for which there is sufficient confidence in a reduced risk of CVD in the general adult population.
- A sodium intake of **2.0 g/day** is likely to allow most of the general population to maintain sodium balance
- 2.0 g of sodium per day is a **safe and adequate intake** for the general EU population of adults



■ Safe:

- The concept of a safe intake has been used when providing advice on a daily intake of a nutrient which does not give rise to concerns about adverse health effects, in case a tolerable upper intake level (UL) could not be established.
- The reference value for Na is called 'safe' as the value proposed takes account of an increased risk of CVD at higher levels of Na intake and prolonged exposure.

■ Adequate:

- An adequate intake (AI) is the value estimated when a population reference intake (PRI) cannot be established because an average requirement (AR) cannot be determined.
- It involves more expert judgement than is used for determining an AR or PRI.
- An AI is similar to a PRI from a practical point of view. The distinction in the terms relates to the different strength of the scientific basis on which they rest.
- The reference value for Na is called 'adequate' in line with this definition.

- Requirement for the daily accretion rate of sodium in fetal and maternal tissues can be met by **adaptive changes** that maintain Na homeostasis during pregnancy
- **No evidence** that Na requirement of lactating women differs from the requirement of non-lactating women
- 2.0 g sodium per day is a safe and adequate intake for pregnant and lactating women

- **Lack of data** from which an AR could be derived for infants
- **Upwards extrapolation** from the estimated Na intake of **fully breast-fed infants** during the first 6 months of life (120 mg/day)
- Adequate Intake of 0.2 g/day proposed for infants aged 7–11 months

- **Lack of data** from which an AR could be derived for children
- **Downwards extrapolation** from the reference value for **adults**, based on the AR for **energy** and including a **growth factor**
- $\text{Value}_{\text{child}} = \text{Value}_{\text{adult}} \times (\text{AR for energy of children} / \text{AR for energy of adults aged 18–29 years}) \times (1 + \text{growth factor})$

	Adequate Intake (g/day)
7–11 months	0.2

	Safe and Adequate Intake (g/day)
1–3 years	1.1
4–6 years	1.3
7–10 years	1.7
11–17 years	2.0
≥ 18 years	2.0

- Moderating effect of **energy intake** on the relationship between sodium intake and blood pressure
- Health effects of sodium and of the **Na/K ratio** at intakes approximating their respective DRVs
- **Life course effects** of Na intake on blood pressure, in particular the effect of Na intake on neurohormonal control during childhood (programming);
- Effect of prolonged exposure to 'low' Na on the effective functioning of its **homeostatic regulation** (i.e. SNS and RAAS)
- Effects of Na intake on **bone health** in growing and ageing populations
- Effects of Na intake on **renal function** in the general population
- Characterisation of genes involved in determining '**salt-sensitive**' phenotypes and of moderating factors of 'salt sensitivity'

Questions & Answers

Part 3

- DRVs for chloride

- Kidney is the main route of excretion; excretion of Na and Cl in urine are closely related
- In Western diets, NaCl is the **major source** of Cl intake which is reflected in the **similar levels of urinary excretion of Na and Cl**, on a molar basis
- Close relationship between Na and Cl balances in the body
- Evidence that chloride can **contribute** to the effect of NaCl on **blood pressure**
- **No studies** on the association between Cl intake or urinary excretion and **cardiovascular diseases**

- No data that can be used to determine Average Requirements and Population Reference Intakes for Cl
- Reference values for Cl can be set at values equimolar to the reference values for Na for all life-stage groups
- Values proposed for chloride are considered to be safe and adequate intakes for the general EU population, under the consideration that the main dietary source of Cl is NaCl

	Adequate Intake (g/day)
7–11 months	0.3

	Safe and Adequate Intake (g/day)
1–3 years	1.7
4–6 years	2.0
7–10 years	2.6
11–17 years	3.1
≥ 18 years	3.1

- As the proportion of NaCl substituted by other Cl salts increases in the diet, to investigate health effects of Cl intake, independent from that of Na

Questions & Answers

- Please submit your comments **by 22 May** through the EFSA website
- Na: <https://www.efsa.europa.eu/en/consultations/call/190403>
- Cl: <https://www.efsa.europa.eu/en/consultations/call/190403-0>



Subscribe to

www.efsa.europa.eu/en/news/newsletters
www.efsa.europa.eu/en/rss



Engage with careers

www.efsa.europa.eu/en/engage/careers



Follow us on Twitter

@efsa_eu
@plants_efsa
@methods_efsa